BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003;40:676-81. [PMID: 12960213 DOI: 10.1136/jmg.40.9.676] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Zipfel PF, Heinen S, Józsi M, Skerka C. Complement and diseases: Defective alternative pathway control results in kidney and eye diseases. Molecular Immunology 2006;43:97-106. [DOI: 10.1016/j.molimm.2005.06.015] [Cited by in Crossref: 156] [Cited by in F6Publishing: 138] [Article Influence: 9.8] [Reference Citation Analysis]
2 Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12:3385-3395. [PMID: 14583443 DOI: 10.1093/hmg/ddg363] [Cited by in Crossref: 230] [Cited by in F6Publishing: 209] [Article Influence: 12.1] [Reference Citation Analysis]
3 Frémeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Dürrbach A. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant. 2007;7:2047-2051. [PMID: 17617869 DOI: 10.1111/j.1600-6143.2007.01888.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
4 Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of aHUS and HELLP. British Journal of Haematology 2008;143:336-48. [DOI: 10.1111/j.1365-2141.2008.07324.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
5 Schulte-Kemna L, Reister B, Bettac L, Ludwig U, Fürst D, Mytilineos J, Bergmann C, van Erp R, Schröppel B. Eculizumab in chemotherapy-induced thrombotic microangiopathy. Clin Nephrol Case Stud 2020;8:25-32. [PMID: 32318323 DOI: 10.5414/CNCS109836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Boulat C, Clero B. Évolution des indications et de la consommation du plasma frais congelé de 1997 à 2003 dans un hôpital universitaire. Transfusion Clinique et Biologique 2005;12:251-6. [DOI: 10.1016/j.tracli.2005.04.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
7 Bhattacharjee A, Lehtinen MJ, Kajander T, Goldman A, Jokiranta TS. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d. Mol Immunol 2010;47:1686-91. [PMID: 20378178 DOI: 10.1016/j.molimm.2010.03.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
8 Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007;96:141-77. [PMID: 17981206 DOI: 10.1016/S0065-2776(07)96004-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
9 Jokiranta TS, Jaakola VP, Lehtinen MJ, Pärepalo M, Meri S, Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J 2006;25:1784-94. [PMID: 16601698 DOI: 10.1038/sj.emboj.7601052] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 7.9] [Reference Citation Analysis]
10 Goodship TH, Liszewski M, Kemp EJ, Richards A, Atkinson JP. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends in Molecular Medicine 2004;10:226-31. [DOI: 10.1016/j.molmed.2004.03.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
11 Kavanagh D, Goodship TH. Update on evaluating complement in hemolytic uremic syndrome. Curr Opin Nephrol Hypertens. 2007;16:565-571. [PMID: 18089972 DOI: 10.1097/mnh.0b013e3282f0872f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
12 Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:111-22. [PMID: 16882452 DOI: 10.1016/j.molimm.2006.07.004] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 6.1] [Reference Citation Analysis]
13 Holle J, Berenberg-goßler L, Wu K, Beringer O, Kropp F, Müller D, Thumfart J. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Pediatr Nephrol 2018;33:2289-98. [DOI: 10.1007/s00467-018-4034-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Jokiranta TS. C3b and factor H: key components of the complement system. Expert Rev Clin Immunol 2006;2:775-86. [PMID: 20477632 DOI: 10.1586/1744666X.2.5.775] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Le Quintrec M, Zuber J, Noel LH, Thervet E, Frémeaux-Bacchi V, Niaudet P, Fridman WH, Legendre C, Dragon-Durey MA. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant. 2009;9:1223-1229. [PMID: 19422347 DOI: 10.1111/j.1600-6143.2009.02586.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
16 Chapin J, Eyler S, Smith R, Tsai HM, Laurence J. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood. 2013;121:4012-4013. [PMID: 23660864 DOI: 10.1182/blood-2013-03-487694] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
17 Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008;8:1694-1701. [PMID: 18557729 DOI: 10.1111/j.1600-6143.2008.02297.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 97] [Article Influence: 8.2] [Reference Citation Analysis]
18 Pechtl IC, Kavanagh D, McIntosh N, Harris CL, Barlow PN. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 2011;286:11082-90. [PMID: 21270465 DOI: 10.1074/jbc.M110.211839] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
19 Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet. 2003;362:1542-1547. [PMID: 14615110 DOI: 10.1016/s0140-6736(03)14742-3] [Cited by in Crossref: 239] [Cited by in F6Publishing: 71] [Article Influence: 13.3] [Reference Citation Analysis]
20 Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, Strain L, Sebire N, Shroff R, Marks SD. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant. 2010;10:168-172. [PMID: 19951285 DOI: 10.1111/j.1600-6143.2009.02870.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
21 Herbert AP, Soares DC, Pangburn MK, Barlow PN. Disease-associated sequence variations in factor H: a structural biology approach. Adv Exp Med Biol 2006;586:313-27. [PMID: 16893081 DOI: 10.1007/0-387-34134-X_21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Gorgi Y, Hbibi I, Sfar I, Gargueh T, Cherif M, Goucha Louzir R, Daghbouj R, Aouadi H, Makhlouf M, Ben Romdhane T, Jendoubi-Ayed S, Amri M, Kheder A, Lakhoua MR, Ben Abdallah T, Ayed K. Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy. Int J Nephrol Renovasc Dis 2010;3:27-32. [PMID: 21694925 DOI: 10.2147/ijnrd.s8442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Zipfel PF, Neumann HP, J??zsi M. Genetic screening in haemolytic uraemic syndrome: . Current Opinion in Nephrology and Hypertension 2003;12:653-7. [DOI: 10.1097/00041552-200311000-00014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 Nangaku M, Nishi H, Fujita T. Pathogenesis and prognosis of thrombotic microangiopathy. Clin Exp Nephrol 2007;11:107-14. [DOI: 10.1007/s10157-007-0466-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
25 Gaut JP, Jain S, Pfeifer JD, Vigh-Conrad KA, Corliss M, Sharma MK, Heusel JW, Cottrell CE. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol 2017;30:1739-47. [PMID: 28752844 DOI: 10.1038/modpathol.2017.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2009;20:940-949. [PMID: 19092117 DOI: 10.1681/asn.2008080906] [Cited by in Crossref: 127] [Cited by in F6Publishing: 51] [Article Influence: 9.1] [Reference Citation Analysis]
27 Ueda Y, Gullipalli D, Song WC. Modeling complement-driven diseases in transgenic mice: Values and limitations. Immunobiology 2016;221:1080-90. [PMID: 27371974 DOI: 10.1016/j.imbio.2016.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
28 Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system]. Rev Med Interne 2011;32:232-40. [PMID: 21376430 DOI: 10.1016/j.revmed.2009.09.039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
29 Jönsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG, Bengtsson A, Zickert A, Eloranta ML, Truedsson L, Rönnblom L, Nordmark G, Sturfelt G, Blom AM. Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 2011;13:R206. [PMID: 22171659 DOI: 10.1186/ar3539] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
30 Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005;14:703-12. [PMID: 15661753 DOI: 10.1093/hmg/ddi066] [Cited by in Crossref: 207] [Cited by in F6Publishing: 191] [Article Influence: 12.2] [Reference Citation Analysis]
31 Tchepeleva SN, Thurman JM, Ruff K, Perkins SJ, Morel L, Boackle SA. An allelic variant of Crry in the murine Sle1c lupus susceptibility interval is not impaired in its ability to regulate complement activation. J Immunol 2010;185:2331-9. [PMID: 20660348 DOI: 10.4049/jimmunol.1000783] [Reference Citation Analysis]
32 Kavanagh D, Richards A, Fremeaux-Bacchi V, Noris M, Goodship T, Remuzzi G, Atkinson JP. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2007;2:591-6. [PMID: 17699467 DOI: 10.2215/CJN.03270906] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
33 Jokiranta TS, Zipfel PF, Fremeaux-bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Molecular Immunology 2007;44:3889-900. [DOI: 10.1016/j.molimm.2007.06.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
34 Blom AM, Bergström F, Edey M, Diaz-Torres M, Kavanagh D, Lampe A, Goodship JA, Strain L, Moghal N, McHugh M, Inward C, Tomson C, Frémeaux-Bacchi V, Villoutreix BO, Goodship TH. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008;180:6385-91. [PMID: 18424762 DOI: 10.4049/jimmunol.180.9.6385] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
35 Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. [PMID: 28056875 DOI: 10.1186/s12882-016-0420-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
36 Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses 2013;81:400-3. [PMID: 23786906 DOI: 10.1016/j.mehy.2013.05.030] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
37 Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat 2006;27:21-30. [PMID: 16281287 DOI: 10.1002/humu.20268] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
38 Noris M, Remuzzi G. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Nat Clin Pract Nephrol 2005;1:2-3. [PMID: 16932353 DOI: 10.1038/ncpneph0018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
39 Olaciregui Echenique I, Areses Trapote R, Ubetagoyena Arrieta M, Sota Busselo I, García Pardos C, Echaniz Aizpuru P. [Incomplete hemolytic uremic syndrome associated with partial factor H deficiency]. An Pediatr (Barc) 2007;66:188-90. [PMID: 17306107 DOI: 10.1157/13098939] [Reference Citation Analysis]
40 Johnson S, Taylor CM. Hemolytic Uremic Syndrome. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1155-80. [DOI: 10.1007/978-3-540-76341-3_48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-33. [PMID: 22986360 DOI: 10.1038/nrneph.2012.195] [Cited by in Crossref: 247] [Cited by in F6Publishing: 218] [Article Influence: 24.7] [Reference Citation Analysis]
42 Falcão DA, Reis ES, Paixão-Cavalcante D, Amano MT, Delcolli MI, Florido MP, Albuquerque JA, Moraes-Vasconcelos D, Duarte AJ, Grumach AS, Isaac L. Deficiency of the human complement regulatory protein factor H associated with low levels of component C9. Scand J Immunol 2008;68:445-55. [PMID: 18782275 DOI: 10.1111/j.1365-3083.2008.02152.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
43 Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 2006;3:e431. [PMID: 17076561 DOI: 10.1371/journal.pmed.0030431] [Cited by in Crossref: 145] [Cited by in F6Publishing: 137] [Article Influence: 9.7] [Reference Citation Analysis]
44 Heger A, Kannicht C, Römisch J, Svae T. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas®) and in the universally applicable plasma (Uniplas) in development: ADAMTS13 and factor H levels in Octaplas®/Uniplas. Vox Sanguinis 2007;92:206-12. [DOI: 10.1111/j.1423-0410.2006.00884.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
45 Sánchez-Corral P, Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010;150:529-42. [PMID: 20629662 DOI: 10.1111/j.1365-2141.2010.08295.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
46 Niaudet P. Living donor kidney transplantation in patients with hereditary nephropathies. Nat Rev Nephrol 2010;6:736-43. [DOI: 10.1038/nrneph.2010.122] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
47 Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol 2019;10:853. [PMID: 31118930 DOI: 10.3389/fimmu.2019.00853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
48 Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9. [PMID: 17018561 DOI: 10.1136/jmg.2006.045328] [Cited by in Crossref: 211] [Cited by in F6Publishing: 187] [Article Influence: 13.2] [Reference Citation Analysis]
49 Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, Pinomäki A, Armstrong E, Koivusalo A, Tukiainen E, Mäkisalo H, Saland J, Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 2008;8:216-21. [PMID: 17973958 DOI: 10.1111/j.1600-6143.2007.02029.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 35] [Article Influence: 0.1] [Reference Citation Analysis]
50 Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, Benchimol C, Seikaly MG, Emre SH, Bresin E, Remuzzi G. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:201-206. [PMID: 19005013 DOI: 10.2215/cjn.02170508] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
51 Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115:379-387. [PMID: 19861685 DOI: 10.1182/blood-2009-05-221549] [Cited by in Crossref: 239] [Cited by in F6Publishing: 214] [Article Influence: 18.4] [Reference Citation Analysis]
52 Skerka C, Józsi M. Role of complement and Factor H in hemolytic uremic syndrome. In: Zipfel PF, editor. Complement and Kidney Disease. Basel: Birkhäuser-Verlag; 2006. pp. 85-109. [DOI: 10.1007/3-7643-7428-4_6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98:1205-1212. [PMID: 24933457 DOI: 10.1097/tp.0000000000000200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 5.9] [Reference Citation Analysis]
54 de Jong S, de Breuk A, Volokhina EB, Bakker B, Garanto A, Fauser S, Katti S, Hoyng CB, Lechanteur YTE, van den Heuvel LP, den Hollander AI. Systemic complement levels in patients with age-related macular degeneration carrying rare or low frequency variants in the CFH gene. Hum Mol Genet 2021:ddab256. [PMID: 34508573 DOI: 10.1093/hmg/ddab256] [Reference Citation Analysis]
55 Habibi I, Sfar I, Ben Alaya W, Methlouthi J, Ayadi A, Brahim M, Blouin J, Dhagbouj R, Ben Rhomdhane T, Makhlouf M, Aouadi H, Ayed-Jendoubi S, Fremeaux-Bacchi V, Sfar T, Ben Abdallah T, Ayed K, Gorgi Y. Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families. Int J Nephrol Renovasc Dis 2010;3:85-92. [PMID: 21694933 DOI: 10.2147/ijnrd.s8373] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
56 Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007;204:1249-1256. [PMID: 17517971 DOI: 10.1084/jem.20070301] [Cited by in Crossref: 201] [Cited by in F6Publishing: 180] [Article Influence: 13.4] [Reference Citation Analysis]
57 Sartz L, Olin AI, Kristoffersson AC, Ståhl AL, Johansson ME, Westman K, Fremeaux-Bacchi V, Nilsson-Ekdahl K, Karpman D. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012;188:2030-7. [PMID: 22250080 DOI: 10.4049/jimmunol.1100319] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
58 Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035-1050. [PMID: 15728781 DOI: 10.1681/asn.2004100861] [Cited by in Crossref: 333] [Cited by in F6Publishing: 108] [Article Influence: 19.6] [Reference Citation Analysis]
59 Thompson CL, Klein BE, Klein R, Xu Z, Capriotti J, Joshi T, Leontiev D, Lee KE, Elston RC, Iyengar SK. Complement factor H and hemicentin-1 in age-related macular degeneration and renal phenotypes. Human Molecular Genetics 2007;16:2135-48. [DOI: 10.1093/hmg/ddm164] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
60 Hahn H, Um EY, Park YS, Cheong HI. A case of atypical hemolytic uremic syndrome with a transient decrease in complement factor H. Pediatr Nephrol 2006;21:295-8. [DOI: 10.1007/s00467-005-2108-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants in the CFH gene. Molecular Immunology 2009;46:1573-94. [DOI: 10.1016/j.molimm.2009.02.013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
62 Ali N, Auerbach HE. New-onset acute thrombocytopenia in hospitalized patients: pathophysiology and diagnostic approach. J Community Hosp Intern Med Perspect 2017;7:157-67. [PMID: 28808508 DOI: 10.1080/20009666.2017.1335156] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
63 Dragon-durey M, Frémeaux-bacchi V. Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immun 2005;27:359-74. [DOI: 10.1007/s00281-005-0003-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
64 Cortina G, Trojer R, Waldegger S, Schneeberger S, Gut N, Hofer J. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus. Pediatr Nephrol. 2015;30:693-697. [PMID: 25577332 DOI: 10.1007/s00467-014-3036-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
65 Geerlings MJ, Volokhina EB, de Jong EK, van de Kar N, Pauper M, Hoyng CB, van den Heuvel LP, den Hollander AI. Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration. Clin Genet 2018;94:330-8. [PMID: 29888403 DOI: 10.1111/cge.13392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
66 Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005;45:415-21. [PMID: 15685522 DOI: 10.1053/j.ajkd.2004.10.018] [Cited by in Crossref: 94] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
67 Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
68 Ferrara D, Seddon JM. Phenotypic Characterization of Complement Factor H R1210C Rare Genetic Variant in Age-Related Macular Degeneration. JAMA Ophthalmol 2015;133:785-91. [PMID: 25880396 DOI: 10.1001/jamaophthalmol.2015.0814] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
69 Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010;74:17-26. [PMID: 20059470 DOI: 10.1111/j.1469-1809.2009.00554.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
70 Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 2016;71:10-22. [DOI: 10.1016/j.molimm.2016.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
71 Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007;22:874-80. [PMID: 17295030 DOI: 10.1007/s00467-007-0438-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
72 Caprioli J, Peng L, Remuzzi G. The hemolytic uremic syndromes: . Current Opinion in Critical Care 2005;11:487-92. [DOI: 10.1097/01.ccx.0000176688.10810.30] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
73 Mukai S, Hidaka Y, Hirota-kawadobora M, Matsuda K, Fujihara N, Takezawa Y, Kubota S, Koike K, Honda T, Yamauchi K. Factor H gene variants in Japanese: Its relation to atypical hemolytic uremic syndrome. Molecular Immunology 2011;49:48-55. [DOI: 10.1016/j.molimm.2011.07.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
74 Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71. [PMID: 18575887 DOI: 10.1007/s00431-008-0745-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
75 Dobó J, Kocsis A, Gál P. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases. Front Immunol 2018;9:1851. [PMID: 30135690 DOI: 10.3389/fimmu.2018.01851] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
76 Mohlin FC, Nilsson SC, Levart TK, Golubovic E, Rusai K, Müller-Sacherer T, Arbeiter K, Pállinger É, Szarvas N, Csuka D, Szilágyi Á, Villoutreix BO, Prohászka Z, Blom AM. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients. Mol Immunol 2015;65:367-76. [PMID: 25733390 DOI: 10.1016/j.molimm.2015.02.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
77 Guigonis V, Frémeaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z, Mougenot B, Rosenblatt DS, Deschênes G. Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005;45:588-95. [PMID: 15754282 DOI: 10.1053/j.ajkd.2004.12.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
78 Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88-99. [PMID: 17699195 DOI: 10.2215/cjn.00050505] [Cited by in Crossref: 174] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
79 Ding Y, Zhao W, Zhang T, Qiang H, Lu J, Su X, Wen S, Xu F, Zhang M, Zhang H, Zeng C, Liu Z, Chen H. A haplotype in CFH family genes confers high risk of rare glomerular nephropathies. Sci Rep 2017;7:6004. [PMID: 28729648 DOI: 10.1038/s41598-017-05173-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
80 Saab KR, Elhadad S, Copertino D, Laurence J. Thrombotic Microangiopathy in the Setting of HIV Infection: A Case Report and Review of the Differential Diagnosis and Therapy. AIDS Patient Care STDS 2016;30:359-64. [PMID: 27509235 DOI: 10.1089/apc.2016.0124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
81 Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol 2017;84:65-76. [PMID: 27939104 DOI: 10.1016/j.molimm.2016.11.016] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]
82 Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431-42. [PMID: 20526633 DOI: 10.1007/s00467-010-1555-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 9.8] [Reference Citation Analysis]
83 Lhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, Würzner R, Zimmerhackl LB, Mayer G, Fremeaux-Bacchi V. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol. 2009;4:1356-1362. [PMID: 19590060 DOI: 10.2215/cjn.06281208] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
84 Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176:1305-10. [PMID: 16424154 DOI: 10.4049/jimmunol.176.3.1305] [Cited by in Crossref: 288] [Cited by in F6Publishing: 271] [Article Influence: 18.0] [Reference Citation Analysis]
85 Ueda Y, Mohammed I, Song D, Gullipalli D, Zhou L, Sato S, Wang Y, Gupta S, Cheng Z, Wang H, Bao J, Mao Y, Brass L, Zheng XL, Miwa T, Palmer M, Dunaief J, Song WC. Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood 2017;129:1184-96. [PMID: 28057640 DOI: 10.1182/blood-2016-07-728253] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
86 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
87 Vaziri-sani F, Holmberg L, Sjöholm A, Kristoffersson A, Manea M, Frémeaux-bacchi V, Fehrman-ekholm I, Raafat R, Karpman D. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney International 2006;69:981-8. [DOI: 10.1038/sj.ki.5000155] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
88 Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant. 2006;6:1948-1952. [PMID: 16889549 DOI: 10.1111/j.1600-6143.2006.01375.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 5.9] [Reference Citation Analysis]
89 Connaughton DM, Hildebrandt F. Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrol Dial Transplant 2020;35:390-7. [PMID: 30809662 DOI: 10.1093/ndt/gfz028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
90 Jokiranta TS, Cheng ZZ, Seeberger H, Jòzsi M, Heinen S, Noris M, Remuzzi G, Ormsby R, Gordon DL, Meri S, Hellwage J, Zipfel PF. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol 2005;167:1173-81. [PMID: 16192651 DOI: 10.1016/S0002-9440(10)61205-9] [Cited by in Crossref: 93] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
91 Oppermann M, Manuelian T, Józsi M, Brandt E, Jokiranta TS, Heinen S, Meri S, Skerka C, Götze O, Zipfel PF. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006;144:342-52. [PMID: 16634809 DOI: 10.1111/j.1365-2249.2006.03071.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 118] [Article Influence: 7.6] [Reference Citation Analysis]
92 Heinen S, Józsi M, Hartmann A, Noris M, Remuzzi G, Skerka C, Zipfel PF. Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells. JASN 2007;18:506-14. [DOI: 10.1681/asn.2006091069] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
93 Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008;3:249-77. [PMID: 18215115 DOI: 10.1146/annurev.pathmechdis.3.121806.154311] [Cited by in Crossref: 139] [Cited by in F6Publishing: 106] [Article Influence: 9.9] [Reference Citation Analysis]
94 Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006;17:2017-2025. [PMID: 16762990 DOI: 10.1681/asn.2005101051] [Cited by in Crossref: 177] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
95 Ormsby RJ, Jokiranta TS, Duthy TG, Griggs KM, Sadlon TA, Giannakis E, Gordon DL. Localization of the third heparin-binding site in the human complement regulator factor H1. Molecular Immunology 2006;43:1624-32. [DOI: 10.1016/j.molimm.2005.09.012] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
96 Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S, Gowrisankar S, Vemuri S, Montgomery K, Yu Y, Reynolds R, Zack DJ, Campochiaro B, Campochiaro P, Katsanis N, Daly MJ, Seddon JM. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet 2011;43:1232-6. [PMID: 22019782 DOI: 10.1038/ng.976] [Cited by in Crossref: 209] [Cited by in F6Publishing: 203] [Article Influence: 19.0] [Reference Citation Analysis]
97 Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Diagn Pathol. 2016;11:94. [PMID: 27717365 DOI: 10.1186/s13000-016-0547-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
98 Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Cnaan A, Trachtman H. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;43:976-82. [PMID: 15168377 DOI: 10.1053/j.ajkd.2004.02.010] [Cited by in Crossref: 142] [Cited by in F6Publishing: 107] [Article Influence: 8.4] [Reference Citation Analysis]
99 Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34:e00146. [PMID: 25188723 DOI: 10.1042/BSR20140117] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
100 de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology. 2012;217:1034-1046. [PMID: 22964229 DOI: 10.1016/j.imbio.2012.07.021] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 8.9] [Reference Citation Analysis]
101 Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008;151:210-30. [PMID: 18190458 DOI: 10.1111/j.1365-2249.2007.03574.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 111] [Article Influence: 9.3] [Reference Citation Analysis]
102 Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Bock A, Wiech T, Gaspert A, Fehr T, Woznowski M, Berisha G, Malinoc A, Goek ON, Eng C, Neumann HP. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet 2011;75:639-47. [PMID: 21906045 DOI: 10.1111/j.1469-1809.2011.00671.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
103 Goodship TH, Frémeaux-bacchi V, Atkinson JP. Genetic testing in atypical HUS and the role of membrane cofactor protein (MCP; CD46) and Factor I. In: Zipfel PF, editor. Complement and Kidney Disease. Basel: Birkhäuser-Verlag; 2006. pp. 111-27. [DOI: 10.1007/3-7643-7428-4_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
104 Licht C, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 2006;70:42-50. [PMID: 16612335 DOI: 10.1038/sj.ki.5000269] [Cited by in Crossref: 154] [Cited by in F6Publishing: 131] [Article Influence: 9.6] [Reference Citation Analysis]
105 Józsi M, Heinen S, Hartmann A, Ostrowicz CW, Hälbich S, Richter H, Kunert A, Licht C, Saunders RE, Perkins SJ, Zipfel PF, Skerka C. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 2006;17:170-7. [PMID: 16338962 DOI: 10.1681/ASN.2005080868] [Cited by in Crossref: 95] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
106 Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report. Transplant Proc. 2011;43:2097-2101. [PMID: 21693335 DOI: 10.1016/j.transproceed.2011.02.064] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
107 Chauvet S, Berthaud R, Devriese M, Mignotet M, Vieira Martins P, Robe-Rybkine T, Miteva MA, Gyulkhandanyan A, Ryckewaert A, Louillet F, Merieau E, Mestrallet G, Rousset-Rouvière C, Thervet E, Hogan J, Ulinski T, Villoutreix BO, Roumenina L, Boyer O, Frémeaux-Bacchi V. Anti-Factor B Antibodies and Acute Postinfectious GN in Children. J Am Soc Nephrol 2020;31:829-40. [PMID: 32034108 DOI: 10.1681/ASN.2019080851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
108 Klämbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, König J, Vinke T, Montoya C, Sperandio BL, Kirschstein M, Hennies I, Pohl M, Häffner K. Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 2021;36:463-71. [PMID: 32715379 DOI: 10.1007/s00467-020-04714-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
110 Boon CJ, van de Ven JP, Hoyng CB, den Hollander AI, Klevering BJ. Cuticular drusen: Stars in the sky. Progress in Retinal and Eye Research 2013;37:90-113. [DOI: 10.1016/j.preteyeres.2013.08.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
111 Schapiro D, Daga A, Lawson JA, Majmundar AJ, Lovric S, Tan W, Warejko JK, Fessi I, Rao J, Airik M, Gee HY, Schneider R, Widmeier E, Hermle T, Ashraf S, Jobst-Schwan T, van der Ven AT, Nakayama M, Shril S, Braun DA, Hildebrandt F. Panel sequencing distinguishes monogenic forms of nephritis from nephrosis in children. Nephrol Dial Transplant 2019;34:474-85. [PMID: 30295827 DOI: 10.1093/ndt/gfy050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
112 Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-63. [PMID: 15590760 DOI: 10.1681/ASN.2004050380] [Cited by in Crossref: 362] [Cited by in F6Publishing: 135] [Article Influence: 20.1] [Reference Citation Analysis]
113 Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Frémeaux-Bacchi V, Steiger J. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 2009;24:3548-51. [PMID: 19633317 DOI: 10.1093/ndt/gfp377] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
114 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
115 Niaudet P. Syndrome hémolytique et urémique chez l’enfant. Néphrologie & Thérapeutique 2008;4:34-40. [DOI: 10.1016/j.nephro.2007.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
116 Ferreira VP, Herbert AP, Cortés C, McKee KA, Blaum BS, Esswein ST, Uhrín D, Barlow PN, Pangburn MK, Kavanagh D. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009;182:7009-18. [PMID: 19454698 DOI: 10.4049/jimmunol.0804031] [Cited by in Crossref: 122] [Cited by in F6Publishing: 123] [Article Influence: 9.4] [Reference Citation Analysis]
117 Davin JC, Olie KH, Verlaak R, Horuz F, Florquin S, Weening JJ, Groothoff JW, Strain L, Goodship TH. Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am J Kidney Dis 2006;47:e27-30. [PMID: 16431247 DOI: 10.1053/j.ajkd.2005.11.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
118 Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome: . Current Opinion in Hematology 2010;17:432-8. [DOI: 10.1097/moh.0b013e32833cae86] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
119 Modde F, Agustian PA, Wittig J, Dämmrich ME, Forstmeier V, Vester U, Ahlenstiel T, Froede K, Budde U, Wingen A, Schwarz A, Lovric S, Kielstein JT, Bergmann C, Bachmann N, Nagel M, Kreipe HH, Bröcker V, Bockmeyer CL, Becker JU. Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). Virchows Arch 2013;462:455-64. [DOI: 10.1007/s00428-013-1386-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
120 Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010;25:136-44. [PMID: 19666655 DOI: 10.1093/ndt/gfp388] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
121 Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 2016;12:133-46. [PMID: 26750453 DOI: 10.1038/nrneph.2015.205] [Cited by in Crossref: 163] [Cited by in F6Publishing: 129] [Article Influence: 27.2] [Reference Citation Analysis]
122 Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 2009;127:193-9. [PMID: 19204238 DOI: 10.1001/archophthalmol.2008.551] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
123 Noris M, Remuzzi G. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol 2008;151:199-209. [PMID: 18070148 DOI: 10.1111/j.1365-2249.2007.03558.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
124 Tortajada A, Pinto S, Martínez-Ara J, López-Trascasa M, Sánchez-Corral P, de Córdoba SR. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 2012;81:56-63. [PMID: 21881555 DOI: 10.1038/ki.2011.291] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
125 Schejbel L, Schmidt IM, Kirchhoff M, Andersen CB, Marquart HV, Zipfel P, Garred P. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun. 2011;12:90-99. [PMID: 21270828 DOI: 10.1038/gene.2010.63] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
126 Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med. 2012;70:121-129. [PMID: 22516576 DOI: 10.1093/ndt/gfq010] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 6.7] [Reference Citation Analysis]
127 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
128 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
129 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
130 Abarrategui-Garrido C, Melgosa M, Peña-Carrión A, de Jorge EG, de Córdoba SR, López-Trascasa M, Sánchez-Corral P. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008;52:171-80. [PMID: 18423815 DOI: 10.1053/j.ajkd.2008.01.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
131 Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-1279. [PMID: 16621965 DOI: 10.1182/blood-2005-10-007252] [Cited by in Crossref: 499] [Cited by in F6Publishing: 410] [Article Influence: 31.2] [Reference Citation Analysis]
132 Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-Durey MA, Choi Y, Cheong HI. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009;66:336-40. [PMID: 19531976 DOI: 10.1203/PDR.0b013e3181b1bd4a] [Cited by in Crossref: 51] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
133 Luo S, Hu D, Wang M, Zipfel PF, Hu Y. Complement in Hemolysis- and Thrombosis- Related Diseases. Front Immunol 2020;11:1212. [PMID: 32754149 DOI: 10.3389/fimmu.2020.01212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
134 Berger SP, Roos A, Daha MR. Complement and the kidney: what the nephrologist needs to know in 2006? Nephrol Dial Transplant 2005;20:2613-9. [PMID: 16204271 DOI: 10.1093/ndt/gfi166] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
135 Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Fremeaux-Bacchi V, Skerka C, Zipfel PF, Goodship T, Noris M, Remuzzi G, de Cordoba SR; European Working Party on the Genetics of HUS. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2008;19:639-46. [PMID: 18235085 DOI: 10.1681/ASN.2007080923] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
136 Kavanagh D, Burgess R, Spitzer D, Richards A, Diaz-Torres ML, Goodship JA, Hourcade DE, Atkinson JP, Goodship TH. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation. Mol Immunol 2007;44:3162-7. [PMID: 17368771 DOI: 10.1016/j.molimm.2007.01.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
137 Haapasalo K, Meri S. Regulation of the Complement System by Pentraxins. Front Immunol 2019;10:1750. [PMID: 31428091 DOI: 10.3389/fimmu.2019.01750] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
138 Zipfel PF, Skerka C. Complement dysfunction in hemolytic uremic syndrome. Curr Opin Rheumatol 2006;18:548-55. [PMID: 16896298 DOI: 10.1097/01.bor.0000240370.47336.ae] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
139 Xing C, Sivakumaran TA, Wang JJ, Rochtchina E, Joshi T, Smith W, Mitchell P, Iyengar SK. Complement factor H polymorphisms, renal phenotypes and age-related macular degeneration: the Blue Mountains Eye Study. Genes Immun 2008;9:231-9. [PMID: 18340363 DOI: 10.1038/gene.2008.10] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
140 Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 2017;130:368-72. [PMID: 28461395 DOI: 10.1182/blood-2017-02-770214] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
141 Leban N, Abarrategui-garrido C, Fariza-requejo E, Amiñoso-carbonero C, Pinto S, Chibani JB, Khelil AH, Sánchez-corral P. Factor H and CFHR1 polymorphisms associated with atypical Haemolytic Uraemic Syndrome (aHUS) are differently expressed in Tunisian and in Caucasian populations: CFH and CFHR1 polymorphisms in Tunisians. International Journal of Immunogenetics 2012;39:110-3. [DOI: 10.1111/j.1744-313x.2011.01071.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
142 Zipfel PF, Hallström T, Hammerschmidt S, Skerka C. The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine 2008;26 Suppl 8:I67-74. [PMID: 19388168 DOI: 10.1016/j.vaccine.2008.11.015] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
143 Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C; French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400. [PMID: 17599974 DOI: 10.1681/asn.2006080811] [Cited by in Crossref: 272] [Cited by in F6Publishing: 121] [Article Influence: 18.1] [Reference Citation Analysis]
144 Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78. [PMID: 27452363 DOI: 10.1038/nrneph.2016.99] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
145 Oyen O, Strøm EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer P, Brekke IB. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006;6:412-8. [PMID: 16426329 DOI: 10.1111/j.1600-6143.2005.01184.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
146 Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship TH. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:2150-2155. [PMID: 15917334 DOI: 10.1681/asn.2005010103] [Cited by in Crossref: 190] [Cited by in F6Publishing: 69] [Article Influence: 11.2] [Reference Citation Analysis]
147 Ren Z, Perkins SJ, Love-Gregory L, Atkinson JP, Java A. Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation. Front Med (Lausanne) 2021;8:775280. [PMID: 34912830 DOI: 10.3389/fmed.2021.775280] [Reference Citation Analysis]
148 de Córdoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008;151:1-13. [PMID: 18081690 DOI: 10.1111/j.1365-2249.2007.03552.x] [Cited by in Crossref: 192] [Cited by in F6Publishing: 184] [Article Influence: 13.7] [Reference Citation Analysis]
149 Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, Goodship JA, Fremeaux-Bacchi V, Remuzzi G, Goodship TH, Atkinson JP. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008;45:95-105. [PMID: 17597211 DOI: 10.1016/j.molimm.2007.05.004] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
150 Haapasalo K, Jarva H, Siljander T, Tewodros W, Vuopio-Varkila J, Jokiranta TS. Complement factor H allotype 402H is associated with increased C3b opsonization and phagocytosis of Streptococcus pyogenes. Mol Microbiol 2008;70:583-94. [PMID: 18627465 DOI: 10.1111/j.1365-2958.2008.06347.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
151 Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, Fremeaux-Bacchi V, Trouw LA, Blom AM. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 2007;44:1835-44. [PMID: 17084897 DOI: 10.1016/j.molimm.2006.10.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
152 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]